New York State Common Retirement Fund Relmada Therapeutics, Inc. Transaction History

New York State Common Retirement Fund

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	SELL	$2.22 - $3.54 $26,546 - $42,331	-11,958 Reduced 98.42%	192 $0
Q1 2023 May 02, 2023	SELL	$2.24 - $4.76 $468 - $994	-209 Reduced 1.69%	12,150 $27,000
Q4 2022 Jan 30, 2023	SELL	$2.17 - $35.84 $46,084 - $761,134	-21,237 Reduced 63.21%	12,359 $43,000
Q3 2022 Nov 08, 2022	BUY	$18.3 - $37.02 $245,494 - $496,623	13,415 Added 66.47%	33,596 $1.24 Million
Q2 2022 Aug 04, 2022	BUY	$16.5 - $30.34 $117,760 - $216,536	7,137 Added 54.71%	20,181 $383,000
Q4 2021 Feb 02, 2022	SELL	$16.93 - $26.82 $152 - $241	-9 Reduced 0.07%	13,044 $294,000
Q3 2021 Nov 02, 2021	BUY	$21.86 - $34.77 $852 - $1,356	39 Added 0.3%	13,053 $342,000
Q2 2021 Aug 02, 2021	BUY	$29.55 - $39.15 $3,368 - $4,463	114 Added 0.88%	13,014 $417,000
Q2 2020 Aug 07, 2020	BUY	$31.59 - $49.98 $407,511 - $644,742	12,900 New	12,900 $577,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

Stay updated on New York State Common Retirement Fund with notifications on news.